Ownership and insider activity for Dyne Therapeutics, Inc. (DYN): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs.
Price
| Price | $16.69 (closing price, October 30, 2026) |
| Market Cap | $3.1B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-02 | Posner Brian S | P-Purchase | 2,500 | $40K |
| 2026-09-04 | Friedl-Naderer Johanna | S-Sale | 900 | $22K |
| 2026-09-08 | Friedl-Naderer Johanna | S-Sale | 185 | $3K |
| 2026-09-04 | Kerr Douglas | S-Sale | 3,745 | $91K |
| 2026-09-08 | Kerr Douglas | S-Sale | 1,290 | $24K |
| 2026-09-08 | Cox John | S-Sale | 5,658 | $107K |
| 2026-08-13 | Rhodes Jason P | S-Sale | 268,354 | $7.0M |
| 2026-08-14 | Rhodes Jason P | S-Sale | 1,359,674 | $34.0M |
| 2026-08-13 | Rhodes Jason P | S-Sale | 94,415 | $2.5M |
| 2026-08-13 | Rhodes Jason P | S-Sale | 63,643 | $1.7M |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.78B | $365.0M | $8.1M | $14.6M | $300.9M | $200.8M | $172.1M | $121.6M | $435.4M | $893.4M |
| Short-term Investments | $130.0M | $32.0M | 0 | 0 | $44.5M | $175.7M | $83.9M | $1.5M | $206.8M | $217.2M |
| Receivables | $386.0M | $513.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | $445.0M | $445.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $2.99B | $1.52B | $8.2M | $14.8M | $349.1M | $382.4M | $265.6M | $129.4M | $659.3M | $1.13B |
| Property, Plant & Equipment | $7.12B | $8.88B | $110,000 | $1.5M | $1.9M | $41.0M | $38.4M | $33.4M | $30.0M | $44.8M |
| Goodwill | $799.0M | $772.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $38.0M | $25.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $13.05B | $11.77B | $8.3M | $16.4M | $353.3M | $425.7M | $306.3M | $165.1M | $691.2M | $1.19B |
| Accounts Payable | $332.0M | $367.0M | $518,000 | $1.3M | $3.4M | $4.0M | $5.3M | $22.9M | $6.6M | $8.1M |
| Short-term Debt | $201.0M | $105.0M | 0 | 0 | 0 | 0 | 0 | 0 | $4.8M | $5.0M |
| Total Current Liabilities | $916.0M | $1.05B | $711,000 | $2.4M | $11.0M | $28.7M | $28.1M | $51.1M | $42.3M | $50.6M |
| Long-term Debt | $8.78B | $8.33B | $3.4M | 0 | 0 | 0 | 0 | 0 | 0 | $15.3M |
| Total Liabilities | $11.01B | $9.87B | $13.1M | $2.4M | $11.0M | $57.5M | $54.0M | $73.8M | $61.4M | $214.8M |
| Retained Earnings | -$1.93B | -$1.85B | -$4.9M | -$19.7M | -$79.2M | -$228.5M | -$396.6M | -$632.5M | -$949.9M | -$1.40B |
| Total Equity | $2.04B | $1.90B | -$4.9M | $14.0M | $342.4M | $368.2M | $252.4M | $91.3M | $629.8M | $972.1M |
| Total Debt | $8.98B | $8.43B | $3.4M | 0 | 0 | $32.6M | $30.5M | $27.4M | $24.0M | $20.3M |
| Net Debt | $7.07B | $8.04B | -$4.7M | -$14.6M | -$345.3M | -$343.9M | -$225.5M | -$95.7M | -$618.3M | -$1.09B |
| Working Capital | $2.07B | $475.0M | $7.4M | $12.4M | $338.1M | $353.7M | $237.5M | $78.3M | $617.0M | $1.08B |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 12.02 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 5.16 |
Profitability
| Return on Equity | -64.30% |
| Return on Invested Capital | -58.28% |
| Return on Assets | -52.25% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: IONS · PTCT · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of DYN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks